Company Overview and News

0
NTB / Bank of N.T. Butterfield & Son Limited (The) null

2018-06-24 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-"B6UM;6U#0HQ(# @;V)J#0H\/"]4>7!E+T-A=&%L;V7!E+U!A9V5S+T-O=6YT(#(O2VED7!E+U!A9V4O4&%R96YT(#(@,"!2+U)E M'0O M26UA9V5"+TEM86=E0R]);6%G94E=(#X^+TUE9&EA0F]X6R P(# @-C$R(#2]#4R]$979I8V521T(^/B]486)S+U,O4W1R=6-T4&%R96YT
NTB

0
NTB / Bank of N.T. Butterfield & Son Limited (The) null

2018-06-24 sec.gov
Document VIA EDGAR AND FEDERAL EXPRESS
NTB

0
NTB / Bank of N.T. Butterfield & Son Limited (The) null

2018-06-24 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C0S(# @;V)J#3P\+TQI;F5A
NTB

14
UBS Group AG's Ratings Upgraded by Moody's, Outlook Stable

2018-06-19 zacks
Long-term ratings for UBS Group AG (UBS - Free Report) , along with long-term senior unsecured debt and deposit ratings have been upgraded by Moody's Investors Service — a rating arm of Moody’s Corporation (MCO - Free Report) . Notably, the outlook on the long-term deposit and senior unsecured ratings has been revised to stable from rating under review. UBS Group AG's long-term deposit rating of Aa3 has been upgraded to Aa2, and A1 long-term issuer and senior unsecured debt ratings have been raised to Aa3.
BMO UBS NTB UBS.PRDCL BMO MCO ULSGF

15
Deutsche Bank to Divest Distressed Shipping Loan Portfolio

2018-06-18 zacks
Per a Reuters article, Deutsche Bank (DB - Free Report) is selling its non-performing ship loan portfolio, which has a notional value of $1 billion to Oak Hill Advisors and Varde investors.
BAP DB NTB

12
HSBC to Focus on Growth and Expansion for Higher Profits

2018-06-12 zacks
With a view to boost profitability, HSBC Holding plc’s (HSBC - Free Report) CEO John Flint has announced plans to invest about $15-$17 billion in technology and expansion of operations by 2020.
BAP NTB TRI

18
Deutsche Bank Seeks to Divest $3B Energy Loan Portfolio

2018-06-08 zacks
Per a Bloomberg article, Deutsche Bank (DB - Free Report) is looking for a suitable buyer for its non-investment grade energy loans portfolio worth nearly $3 billion. Moreover, the energy segment is expected to be closed by end of this quarter
BAP DB UNP NTB

15
Deutsche Targets Majority Cost Savings From Investment Bank

2018-06-07 zacks
Of the €2 billion cost cuts announced in May 2018, Deutsche Bank (DB - Free Report) expects to see more than half of the savings from its investment banking segment. Chief Financial Officer, James Von Moltke, also indicated that the Germany-based lender might continue to lag its peers in performance in the second quarter.
BAP DB NTB

15
Royal Bank of Scotland Stock Down as Government Sells Stake

2018-06-05 zacks
The British government sold 7.7% stake in Royal Bank of Scotland (RBS - Free Report) , in sync with its efforts to return the bank to private ownership. The sale resulted in substantial loss for the taxpayers, owing to a significant drop in the value of the stock since the time government had bailed out the bank during the financial crisis. Following the announcement of the news, the bank’s shares on NYSE have fallen nearly 2% in the pre-market trading.
BAP DB NTB

15
Deutsche Bank (DB) to Cut Down Operations in South Africa

2018-06-05 zacks
Deutsche Bank (DB - Free Report) is closing corporate broking, advisory and sponsor-service operations at its South African unit in a period of six months, with a view to boost profitability. The bank, however, refrained from mentioning the number of jobs that will be impacted.
BAP DB NTB

15
Deutsche Stock Falls on Being Listed Troubled by Regulators

2018-06-01 zacks
Per a Wall Street Journal’s article, Deutsche Bank’s (DB - Free Report) U.S. unit was placed under troubled bank’s list by the Federal Reserve almost a year back, following which, the Federal Deposit Insurance Corporation (“FDIC”) put it under its own list of problem banks.
BAP DB NTB

43
Deutsche Bank Sees No Further Job Cuts in Russia Operations

2018-05-30 zacks
Per a Reuters article, Deutsche Bank (DB - Free Report) seeks to spare Russia from its job cut drive and instead focus on strengthening a key business area — commercial banking.
WFC WFCNP WFC.WS BAP DB NTB WFC.PRL WFC.PRJ WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY WFC.PRX WFC.PRW WFC.PRV

14
RBS' Journey to Privatization is Expected to Begin Shortly

2018-05-29 zacks
Per an article by Sky News, the British Government is currently mulling selling about 10% stake in The Royal Bank of Scotland (RBS - Free Report) this week. The sale is expected to result in substantial loss for the taxpayer owing to a significant drop in value of the bank since bailout.
HRL BAP NTB

5
Foreign Banks Stock Outlook: Short-Term Pain is Inevitable

2018-05-29 zacks
Normalization of monetary policy by some central banks across the globe should keep the momentum alive in the foreign banking space, which ended 2017 with a decent recovery. However, near-term growth prospects of foreign banks are being called into question because of the weak recovery witnessed by banks in the advanced nations (except the United States) and continued trouble faced by banks in some of the emerging economies.
BCH 8306 NTB MUFG MBFJF MTU MRC

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to NTB / Bank of N.T. Butterfield & Son Limited (The) on message board site Silicon Investor.

Neptune Technologies u0026 Bioressources Inc. - NTB.V NetBank(NTBK)-formerly Atlanta Internet Bank
Paintball E InvestmentBank (einvestmentbank) IPO Alerts
mydiscountbroker.com USAB (http://www.usabancshares.com) v.s. NTBK
NTBM -- NU TECH BIO MED, INC SDMT - EBLD - Entertainmentblvd.com
NETBANK (NTBK)
CUSIP: G0772R208